Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF
Key facts
- Who runs it
- Hitit University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 10 Jul 2025
- Ended
- 11 May 2026
- Type of study
- Observational, 2 groups
- Record updated
- 15 September 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Confirmed diagnosis of Familial Mediterranean Fever (FMF) according to Tel-Hashomer clinical criteria and/or MEFV gene mutation analysis (for FMF group)
- Undergoing routine endoscopy with mucosal biopsy sampling
- Availability of sufficient formalin-fixed paraffin-embedded (FFPE) tissue for immunohistochemical analysis
- For controls: absence of systemic inflammatory or autoimmune disease -
Who cannot take part
- Current use of immunosuppressive therapy (excluding colchicine)
- Severe infection, active malignancy, or other systemic disease affecting intestinal mucosa
- Inadequate biopsy specimen quality for histopathological evaluation
- -
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to investigate the intestinal mucosal expression of key inflammatory markers, namely Interleukin-1 (IL-1), Interleukin-18 (IL-18), and Caspase-1, in patients with Familial Mediterranean Fever (FMF). FMF is an autoinflammatory disorder characterized by recurrent episodes of fever and serosal inflammation. Recent studies suggest a possible role of intestinal immune activation in the disease pathogenesis, particularly through inflammasome-related cytokines. To better understand mucosal involvement in FMF, immunohistochemical staining for IL-1, IL-18, and Caspase-1 will be performed on intestinal biopsy samples obtained during routine endoscopic procedures. The staining intensity and distribution patterns will be evaluated and compared with age- and sex-matched healthy controls. The findings may help clarify mucosal inflammatory pathways involved in FMF and provide insight into novel therapeutic targets.
The 2 groups in the trial
- Grup 1: Group Title: FMF Patients Group/Cohort Label: FMF
1\. FMF Patients (Group/Cohort Description) Patients diagnosed with Familial Mediterranean Fever (FMF) according to clinical criteria and/or genetic analysis. Intestinal mucosal biopsy samples were obtained during routine endoscopy, and immunohistochemical staining for IL-1, IL-18, and Caspase-1 was performed.
- Grup 2: Group Title: Healthy Controls Group/Cohort Label: Control
2\. Healthy Controls (Group/Cohort Description) Healthy individuals without any known inflammatory or autoimmune disease, undergoing endoscopy for non-inflammatory indications such as functional gastrointestinal symptoms. Mucosal biopsy samples were collected and analyzed immunohistochemically for IL-1, IL-18, and Caspase-1 expression.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Caspase-1 Activity, IL-1beta, and IL-18 on Inflammation in the Mucosa of the Small Intestine of Patients With FMF
- Record updated
- 15 September 2026